Ustar has recently received an approval for our EasyNAT Monkeypox Virus Assay from the Medicines & Healthcare products Regulatory Agency (MHRA).

According to the latest report of WHO, the number of confirmed cases has exceeded 60,000 cases, affecting more than 100 countries and regions, the European region and regions of the Americas  have become the two largest regions affected by the monkeypox epidemic.

 Source： WHO

Since the CE certification in May this year, our EasyNAT Monkeypox Virus Assay has been sold to the United States, the United Kingdom, Italy, the Netherlands, Spain, Malaysia and other countries and regions, helping more than 30 countries and regions to improve the detection capacity of monkeypox virus, providing a strong guarantee for the prevention and control of monkeypox epidemic with scientific and technological innovation.

EasyNAT® Molecular Testing Platform for Monkeypox Virus

The EasyNAT Molecular Testing Platform for Monkeypox Virus is a highly integrated point-of-care testing system integrating sampling and addition of samples in one step. It is applicable for oropharyngeal swab or skin lesion exudate samples and report result within 30 minutes automatically.

---"Swab in, result out": not require additional VTM&BSC, simple workflow friendly to laymens.
---Biosafe: integrated processes of sample lysis, purification, amplification and detection in a sealed cartridge without the need to open the cartridge twice, maximizing the risk of cross-contamination.
---Applicable for primary-level medical units, tent hospitals, mobile detection, and airport customs.
---Affordable: ambient transportation with glassified reagent reducing shipping costs.